Physician profile
Robert T Toborg
NPI 1003813650
$1,663.87
in general payments reported to CMS, 2019-2025
15 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2021: $14.93 · 2022: $153 · 2023: $486 · 2024: $424 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $278.47 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $268.60 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $261.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $259.61 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $193.54 | 2022-2025 | Freestyle Libre 3 |
| Organon LLC | $75.10 | 2024-2025 | Nexplanon |
| Abbvie INC. | $72.01 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $66.15 | 2025 | Rexulti |
| Boston Scientific Corporation | $46.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.08 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $32.82 | 2023 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.87 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $21.14 | 2024 | Eliquis |
| Amgen INC. | $17.43 | 2025 | Repatha, Otezla |
| Shield Therapeutics INC | $15.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Toborg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.